AVEO (AVEO) Up 71.1% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for AVEO Pharmaceuticals (AVEO). Shares have added about 71.1% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is AVEO due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.

AVEO Q4 Earnings Beat, Revenues Lag

AVEO incurred fourth-quarter 2018 loss of 3 cents per share, narrower than the Zacks Consensus Estimate of a loss of 6 cents and also the year-ago loss of 8 cents.

AVEO’s top line comprises collaboration and licensing revenues plus partnership royalties. Total revenues in the reported quarter were approximately $1.5 million compared with $0.08 million reported in fourth-quarter 2017. Moreover, revenues missed the Zacks Consensus Estimate of $2.5 million.

Operating Expenses

Research & development expenses were down 8.8% year over year to $5.2 million. However, general and administrative expenses increased 8.3% year over year to $2.6 million.

Cash Guidance

AVEO expects that its present cash resources of $24.4 million along with $7.5 million raised from the sales under its agreement with SVB Leerink this February will allow the company to fund its planned operations through the first quarter of 2019.

How Have Estimates Been Moving Since Then?

In the past month, investors have witnessed an upward trend in fresh estimates. The consensus estimate has shifted 29.17% due to these changes.

VGM Scores

Currently, AVEO has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.


Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. It comes with little surprise AVEO has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.

Click to get this free report

AVEO Pharmaceuticals, Inc. (AVEO): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Technology Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More